Navigation Links
South African Tribunal Asks For Damages Estimates in GSK AIDS Drug Case

A landmark South African legal complaint against British drug maker GlaxoSmithKline (GSK) over its AIDS drug pricing and policies in that country will proceed following an order late last week by South Africa's Competition Tribunal that will allow the complaint to go forward. GSK has sought outright dismissal of the case; however, the Competition Tribunal issued an order last week giving the complainants, AIDS Healthcare Foundation (AHF) and several South African AIDS advocates, 10 days to present further evidence & arguments regarding the damages they claim to have sustained as a result of what they claim are GSK's illegal drug pricing and policies. The order also states that the parties will come back in late April or the first week of May 2005 to present oral arguments on these issues.

"In our case, we will submit to the Tribunal evidence of the monetary damages suffered as a result of GSK's illegal actions in charging excessive AIDS drug prices in South Africa," said Michael Weinstein, AHF’s president. “As a result of GSK’s actions, thousands and thousands of South Africans were unable to afford or obtain GSK’s life-saving AIDS drugs, and we believe thousands of those individuals have died of AIDS as a result. We thank the Tribunal for its order allowing our complaint to proceed and we look forward to fully presenting our case against GSK before the Tribunal.?/p>

The complaint was filed with South Africa’s Competition Tribunal in August 2004 by AIDS Healthcare Foundation (AHF), the US?largest AIDS organization and several other South African AIDS advocates. AHF operates the ‘Ithembalabantu?(Zulu for people’s hope) clinic, a free AIDS treatment clinic in Umlazi Township, KwaZulu Natal in partnership with the Network of AIDS Communities of South Africa (NetCom SA) a local non-government organization. In the complaint, AHF and others allege that GSK has charged excessive prices for AIDS drugs to the detriment of South Africans with HIV/AIDS and in vi olation of the Competition Act.

“South Africans know that AIDS drugs are sadly out of reach for most of them because of pricing actions like GSK’s,?said Swazi Hlubi, Executive Director of the Network of AIDS Communities in South Africa (NetCom SA), and a partner with AHF in the Ithembalabantu free AIDS treatment clinic in Durban. “So much so, that more than 100,000 South Africans recently signed a petition calling on GSK to set up an AIDS treatment trust fund to atone for its past AIDS drug pricing and policies here in South Africa. We are grateful for the Tribunal’s order allowing this competition complaint to move forward.?/p>
'"/>

Source:AIDSHealth.org


Related biology news :

1. South Americas vast pantanal wetland may become next everglades, UNU experts warn
2. New Species of Coral Discovered Off Southern California
3. South Africa still debating how to tackle HIV/AIDS when 5 million are infected
4. High carbon dioxide levels spur Southern pines to grow more needles
5. North & South American researchers find architectural abnormalities in T. cruzi ribosome
6. UT Southwestern researchers discover master switch in cell death
7. Drug resistant avian influenza viruses more common in Southeast Asia than North America
8. UT Southwestern researchers develop screening test for cells that activate immune system
9. UT Southwestern researchers unravel control of growing blood vessels
10. Newly discovered birdlike dinosaur is oldest raptor ever found in South America
11. DNA end caps may lead to cancer treatments, UT Southwestern researchers report

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... Durham, NC (PRWEB) , ... June 23, 2016 , ... ... Odense University Hospital in Denmark detail how a patient who developed lymphedema after being ... (fat) tissue. The results could change the paradigm for dealing with this debilitating, frequent ...
Breaking Biology Technology: